Literature DB >> 15252348

Late-onset blebitis/endophthalmitis: incidence and outcomes with mitomycin C.

Elizabeth Draper Muckley1, Richard A Lehrer.   

Abstract

PURPOSE: To assess the outcomes of patients who had late infections after undergoing filtering surgery with mitomycin C with respect to treatment, resultant vision, and maintenance of intraocular pressure.
METHODS: A retrospective review of 233 eyes that underwent trabeculectomy with mitomycin C with or without coincident cataract extraction and intraocular lens insertion from August 1993 to June 1997 was undertaken. Records were examined for postoperative infection occurring at least 6 months after filtering surgery. Age, sex, date, and type of surgery were reviewed and entered into a computerized database.
RESULTS: Bleb infections occurred in 6 of 233 (2.6%) eyes that underwent mitomycin C filtering surgery. Four of these developed endophthalmitis. The average postoperative time until infection was 24.7 months. Two patients had bleb leaks, one of which progressed to endophthalmitis. On resolution of infection, all blebs remained functional, and vision returned to preblebitis acuities in 67%.
CONCLUSION: Aggressive topical antibiotic therapy with daily observation may be appropriate in selected cases of late-onset blebitis and endophthalmitis. Eyes may continue to have good visual outcomes and functioning filters without need for additional surgery or hospitalization. Early recognition and appropriate management of infections may play a role in these outcomes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15252348     DOI: 10.1097/00006324-200407000-00010

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  15 in total

1.  Prevention of ocular scarring after glaucoma filtering surgery using the monoclonal antibody LT1009 (Sonepcizumab) in a rabbit model.

Authors:  Zachary L Lukowski; Jeff Min; Ashley R Beattie; Craig A Meyers; Monica A Levine; Glenn Stoller; Gregory S Schultz; Don A Samuelson; Mark B Sherwood
Journal:  J Glaucoma       Date:  2013-02       Impact factor: 2.503

2.  Trabeculectomy-related complications in Olmsted County, Minnesota, 1985 through 2010.

Authors:  Jessica A Olayanju; Mohamed B Hassan; David O Hodge; Cheryl L Khanna
Journal:  JAMA Ophthalmol       Date:  2015-05       Impact factor: 7.389

3.  Trabeculotomy combined with phacoemulsification, intraocular lens implantation and sinusotomy for exfoliation glaucoma.

Authors:  Takeo Fukuchi; Jun Ueda; Tomoko Nakatsue; Kieko Suda; Hiroaki Hara; Haruki Abe
Journal:  Jpn J Ophthalmol       Date:  2011-05-11       Impact factor: 2.447

4.  Mitomycin C augmented glaucoma surgery: evolution of filtering bleb avascularity, transconjunctival oozing, and leaks.

Authors:  N Anand; S Arora; M Clowes
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

5.  Corneal lamellar grafting to repair late complications of mitomycin C trabeculectomy.

Authors:  Takeo Fukuchi; Hidenobu Matsuda; Jun Ueda; Akiko Yamada; Kieko Suda; Haruki Abe
Journal:  Clin Ophthalmol       Date:  2010-04-26

6.  Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives.

Authors:  M Kernt; A Kampik
Journal:  Clin Ophthalmol       Date:  2010-03-24

7.  Prevention of ocular scarring post glaucoma filtration surgery using the inflammatory cell and platelet binding modulator saratin in a rabbit model.

Authors:  Jeff Min; Zachary L Lukowski; Monica A Levine; Craig A Meyers; Ashley R Beattie; Gregory S Schultz; Don A Samuelson; Mark B Sherwood
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

Review 8.  Endophthalmitis: state of the art.

Authors:  Kamyar Vaziri; Stephen G Schwartz; Krishna Kishor; Harry W Flynn
Journal:  Clin Ophthalmol       Date:  2015-01-08

9.  Incidence of bleb-associated endophthalmitis in the United States.

Authors:  Kamyar Vaziri; Krishna Kishor; Stephen G Schwartz; Arindel S Maharaj; Darius M Moshfeghi; Andrew A Moshfeghi; Harry W Flynn
Journal:  Clin Ophthalmol       Date:  2015-02-12

10.  Blockade of KCa3.1: A novel target to treat TGF-β1 induced conjunctival fibrosis.

Authors:  Govindaraj Anumanthan; Philip J Wilson; Ratnakar Tripathi; Nathan P Hesemann; Rajiv R Mohan
Journal:  Exp Eye Res       Date:  2017-12-12       Impact factor: 3.770

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.